P306 | IICIMED

cyp51A-mediated azole resistance mechanisms involved in Aspergillus fumigatus.

P306

JAC-Antimicrobial Resistance, 2026, 8, 1.

Global epidemiology of azole resistance in Aspergillus fumigatus.


https://doi.org/10.1093/jacamr/dlaf219

P305 | IICIMED

P305

Medical Mycology, 2025, 63, 12.

Multi-fungicide resistance in both clinical and environmental isolates of the human fungal pathogen Aspergillus fumigatus.


https://doi.org/10.1093/mmy/myaf110

P303 | IICIMED

Mapping of amino acid subs tu ons reported in Erg11, Tac1 and Mrr1, respec vely and their possible contribu on to fluconazole resistance

P303

npj Antimicrob. Resist., 2025, 3, 99.

Emerging antifungal resistance in Candida parapsilosis: the end of the innocence.


https://doi.org/10.1038/s44259-025-00173-5

P302 | IICIMED

P302

Inorg. Chem., 2025, 64, 16192-16203. 

Synthesis and Biological Evaluation of Itraconazole Derivatives: Design in an Old Scaffold.


https://doi.org/10.1021/acs.inorgchem.5c02730

P301 | IICIMED

Macroscopic aspect of 14 Diutina catenulata and other species used as comparator strains when grown on CHROMID® Candida agar plates.

P301

J. Med. Mycol. 2025, 101583.

A One Health Perspective on Diutina catenulata: Phenotypic Traits, Stress Sensitivity, and Virulence Across Diverse Isolates.


https://doi.org/10.1016/j.mycmed.2025.101583

P300 | IICIMED

Binding position found by the GOLD docking programme for compound 30 in the ATP pocket of LmCK1.2. Hydrogen bonds are indicated by yellow lines.

P300

RSC Med. Chem. 2025, 16, 3746–3763. 

 Pharmacophore-guided optimization of the hit compound CTN1122 in the design of promising imidazo[1,2-a]pyrazine derivatives targeting the casein kinase 1 for antileishmanial therapy


https://doi.org/10.1039/D5MD00257E

P299 | IICIMED

P299

J. Antimicrob. Chemother. 2025, 80, 472-477.

Assessment of co-resistance to antibiotics recommended for acute pyelonephritis among Escherichia coli clinical strains from community- and nursing home-acquired urinary tract infections.


https://doi.org/10.1093/jac/dkae431

P298 | IICIMED

P298

 JAMA Netw. Open. 2025, 8, e2521165. doi:10.1001/jamanetworkopen.2025.21165

Surgeons’ Contributions to Antibiotic Stewardship and Resistance Prevention.


P295 | IICIMED

Schematic representation of the A. flavus CYP51 genes showing all mutations leading to amino acid substitutions previously reported in the literature.

P295

Mycoses. 2025, 68, e70051

Antifungal Resistance in Non-fumigatus Aspergillus Species.


https://doi.org/10.1111/myc.70051

P294 | IICIMED

P294

Mycopathologia. 2025, 190, 59.

Trichosporon and Antifungal Resistance: Current Knowledge and Gaps.


https://doi.org/10.1007/s11046-025-00969-z

P293 | IICIMED

Estimated phylogeny of 374 Candida parapsilosis isolates, constructed using 96,501 SNP sites.

P293

mBio. 2025, e01320-25.

Small pangenome of Candida parapsilosis reflects overall low intraspecific diversity.


https://doi.org/10.1128/mbio.01320-25

P292 | IICIMED

Mechanisms of action of agricultural fungicides according to FRAC classification.

P292

Sci. Total Environ. 2025, 1000, 180385.

Agrochemical fungicides as environmental drivers of antifungal resistance.


https://doi.org/10.1016/j.scitotenv.2025.180385

P291 | IICIMED

Scatter plots where each point represents a spectrum, with different colours indicating the clades showing Clade I isolates in blue, Clade II isolates in red, Clade III in green, Clade IV in grey.

P291

Mycoses. 2025, 68, e70085.

Clade Distinction and Tracking of Clonal Spread by Fourier-Transform Infrared Spectroscopy in Multicenter candida (Candidozyma) auris Ourbreak.


https://doi.org/10.1111/myc.70085

P290 | IICIMED

Exploring chemical space of CTN1122: antileishmanial activity and L-CK1.2 inhibition.

P290

ChemMedChem. 2025, 20, e202400862.

Investigating the C2 modulation of the imidazo[1,2-a]pyrazine-based hit compound CTN1122: synthesis, in vitro antileishmanial activity, cytotoxicity and casein kinase 1 inhibition.


https://doi.org/10.1002/cmdc.202400862

P289 | IICIMED

Timeline of the drug design and development process of 2-aminothiophenes with antileishmanial activity.

P289

Pharmaceuticals. 2025, 18, 125.

2-Aminothiophene derivatives -New drug canditates against leismaniasis: Drug design, synthesis, pharmacomodulation, and antileishmanial activity.


https://doi.org/10.3390/ph18010125

P304 | IICIMED

P304

Sci Rep, 2025, 16, 2515.

Antifungal and fungicide susceptibility of clinical, animal, and environmental Fusarium and Neocosmospora species from Colombia: a one-health approach.


https://doi.org/10.1038/s41598-025-32234-0

P288 | IICIMED

P288

Nat. Rev. Microbiol. 2024, 22, 636-649.

Healthcare as a driver, reservoir and amplifier of antimicrobial resistance opportunities for interventions.


https://doi.org/10.1038/s41579-024-01076-4

P287 | IICIMED

Structure activity relationship for antileishmanial activity and cytotoxicity.

P287

Eur. J. Med. Chem. Rep. 2024, 12, 100228.

Biological properties and in silico studies of thiazolopyrimidine derivatives active against visceral and cutaneous Leishmania spp. amastigote forms.


https://doi.org/10.1016/j.ejmcr.2024.100228.